WIKIMEDIA, LINDA BARTLETTMapp Biopharmaceutical, whose experimental drug ZMapp was given to a few people infected with Ebola virus, has received a government contract worth more than $42 million. The Biomedical Advanced Research and Development Authority, an office within the US Department of Health and Human Services (HHS), agreed to offer an initial $24.9 million for “funding as well as access to subject matter expertise and technical support for manufacturing, regulatory, and nonclinical activities,” according to a press release.
“While ZMapp has received a lot of attention, it is one of several treatments under development for Ebola, and we still have very limited data on its safety and efficacy,” Nicole Lurie, the assistant secretary for preparedness and response, said in the release.
Last week, researchers reported that ZMapp appeared to cure 18 monkeys of Ebola. Although the drug has also been given to a handful of infected humans, it’s not clear yet whether it has helped them. Subsequently, Mapp had exhausted its supply of the drug.
The San Diego Union-Tribune reported that HHS acted “with unusual speed” to get the money moving. “It’s unusual that things would happen this fast. But there’s a confluence of events,” Michael Gilson, director of the Drug Discovery Institute ...
